195 related articles for article (PubMed ID: 37399894)
1. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.
Chi KN; Sandhu S; Smith MR; Attard G; Saad M; Olmos D; Castro E; Roubaud G; Pereira de Santana Gomes AJ; Small EJ; Rathkopf DE; Gurney H; Jung W; Mason GE; Dibaj S; Wu D; Diorio B; Urtishak K; Del Corral A; Francis P; Kim W; Efstathiou E
Ann Oncol; 2023 Sep; 34(9):772-782. PubMed ID: 37399894
[TBL] [Abstract][Full Text] [Related]
2. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi KN; Rathkopf D; Smith MR; Efstathiou E; Attard G; Olmos D; Lee JY; Small EJ; Pereira de Santana Gomes AJ; Roubaud G; Saad M; Zurawski B; Sakalo V; Mason GE; Francis P; Wang G; Wu D; Diorio B; Lopez-Gitlitz A; Sandhu S;
J Clin Oncol; 2023 Jun; 41(18):3339-3351. PubMed ID: 36952634
[TBL] [Abstract][Full Text] [Related]
3. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
[TBL] [Abstract][Full Text] [Related]
4. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL
J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract][Full Text] [Related]
7. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.
McKay RR; Morgans AK; Shore ND; Dunshee C; Devgan G; Agarwal N
Cancer Treat Rev; 2024 May; 126():102726. PubMed ID: 38613872
[TBL] [Abstract][Full Text] [Related]
8. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Puente J; González-Del-Alba A; Sala-Gonzalez N; Méndez-Vidal MJ; Pinto A; Rodríguez Á; Cuevas Sanz JM; Muñoz Del Toro JR; Useros Rodríguez E; García García-Porrero Á; Vázquez S
BMC Cancer; 2019 Aug; 19(1):766. PubMed ID: 31382926
[TBL] [Abstract][Full Text] [Related]
11. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
[TBL] [Abstract][Full Text] [Related]
12. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N; Azad AA; Carles J; Fay AP; Matsubara N; Heinrich D; Szczylik C; De Giorgi U; Young Joung J; Fong PCC; Voog E; Jones RJ; Shore ND; Dunshee C; Zschäbitz S; Oldenburg J; Lin X; Healy CG; Di Santo N; Zohren F; Fizazi K
Lancet; 2023 Jul; 402(10398):291-303. PubMed ID: 37285865
[TBL] [Abstract][Full Text] [Related]
13. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Thiery-Vuillemin A; de Bono J; Hussain M; Roubaud G; Procopio G; Shore N; Fizazi K; Dos Anjos G; Gravis G; Joung JY; Matsubara N; Castellano D; Degboe A; Gresty C; Kang J; Allen A; Poehlein C; Saad F
Lancet Oncol; 2022 Mar; 23(3):393-405. PubMed ID: 35157830
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Ning YM; Maher VE; Zhang L; Tang S; Ghosh D; Aziz R; Palmby T; Pfuma E; Zirkelbach JF; Mehrotra N; Tilley A; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Dec; 19(24):6650-6. PubMed ID: 24150234
[TBL] [Abstract][Full Text] [Related]
15. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
Saad F; Chi KN; Shore ND; Graff JN; Posadas EM; Lattouf JB; Espina BM; Zhu E; Yu A; Hazra A; De Meulder M; Mamidi RNVS; Bradic B; Francis P; Hayreh V; Rezazadeh Kalebasty A
Cancer Chemother Pharmacol; 2021 Jul; 88(1):25-37. PubMed ID: 33754187
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
Boegemann M; Khaksar S; Bera G; Birtle A; Dopchie C; Dourthe LM; Everaert E; Hatzinger M; Hercher D; Hilgers W; Matus G; Alvarez LG; Antoni L; Lukac M; Pissart G; Robinson P; Elliott T
BMC Cancer; 2019 Jan; 19(1):60. PubMed ID: 30642291
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
18. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Morris MJ; Heller G; Hillman DW; Bobek O; Ryan C; Antonarakis ES; Bryce AH; Hahn O; Beltran H; Armstrong AJ; Schwartz L; Lewis LD; Beumer JH; Langevin B; McGary EC; Mehan PT; Goldkorn A; Roth BJ; Xiao H; Watt C; Taplin ME; Halabi S; Small EJ
J Clin Oncol; 2023 Jun; 41(18):3352-3362. PubMed ID: 36996380
[TBL] [Abstract][Full Text] [Related]
19. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
Matsubara N; de Bono J; Olmos D; Procopio G; Kawakami S; Ürün Y; van Alphen R; Flechon A; Carducci MA; Choi YD; Hotte SJ; Korbenfeld E; Kramer G; Agarwal N; Chi KN; Dearden S; Gresty C; Kang J; Poehlein C; Harrington EA; Hussain M
Clin Cancer Res; 2023 Jan; 29(1):92-99. PubMed ID: 36318705
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With
Fallah J; Xu J; Weinstock C; Brave MH; Bloomquist E; Fiero MH; Schaefer T; Pathak A; Abukhdeir A; Bhatnagar V; Chiu HJ; Ricks T; John C; Hamed S; Lee C; Pierce WF; Kalavar S; Philip R; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman D
J Clin Oncol; 2024 Feb; 42(5):605-613. PubMed ID: 38127780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
